M
Mario Fernández-Ruiz
Researcher at Complutense University of Madrid
Publications - 278
Citations - 6977
Mario Fernández-Ruiz is an academic researcher from Complutense University of Madrid. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 36, co-authored 244 publications receiving 4954 citations. Previous affiliations of Mario Fernández-Ruiz include Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Polymicrobial endocarditis involving Veillonella parvula in an intravenous drug user: case report and literature review of Veillonella endocarditis.
M. A. Pérez-Jacoiste Asín,Mario Fernández-Ruiz,I. Serrano-Navarro,S. Prieto-Rodriguez,José María Aguado +4 more
TL;DR: A 35-year-old man presented to the Emergency Department (ED) of the authors' hospital with fever, chills, purulent sputum, and pleuritic pain for about 48 h, and empiric treatment with IV ceftriaxone, cloxacillin, and gentamicin was initiated.
Journal ArticleDOI
SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered from COVID-19.
Mario Fernández-Ruiz,Beatriz Olea,Estela Giménez,Rocío Laguna-Goya,Hernando Trujillo,Fernando Caravaca-Fontán,Eduardo Gutiérrez,Francisco López-Medrano,María José Remigia,Patricia Almendro-Vázquez,Natalia Polanco,Esther González,Tamara Ruiz-Merlo,Patricia Parra,Rafael San Juan,Amado Andrés,David Navarro,José María Aguado +17 more
TL;DR: The magnitude and kinetics of severe acute respiratory syndrome coronavirus 2-specific cell-mediated immunity (SARS-CoV-2-CMI) in kidney transplant (KT) recipients remain largely unknown.
Journal ArticleDOI
Hierro e infección fúngica invasiva
TL;DR: The present review focuses on the role of iron metabolism in the pathogenesis of IFI and summarises the preclinical data, as well as the limited clinical experience so far, in the use of new iron chelators as treatment for mucormycosis and invasive aspergillosis.
Journal ArticleDOI
Toxin B PCR Amplification Cycle Threshold Adds Little to Clinical Variables for Predicting Outcomes in Clostridium difficile Infection: a Retrospective Cohort Study.
Julia Origüen,María Ángeles Orellana,Mario Fernández-Ruiz,Laura Corbella,Rafael San Juan,María Ruiz-Ruigómez,Francisco López-Medrano,Manuel Lizasoain,Tamara Ruiz-Merlo,Guillermo Maestro de la Calle,Patricia Parra,Jennifer Villa,Rafael Delgado,José María Aguado +13 more
TL;DR: Despite the inverse correlation between PCR CT and the risk of CDI recurrence/severity, this determination does not meaningfully increase the predictive value of clinical variables plus toxin EIA.
Journal ArticleDOI
Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature.
José Tiago Silva,V. Pérez-González,Francisco López-Medrano,Rodrigo Alonso-Moralejo,Mario Fernández-Ruiz,Rafael San-Juan,Patricia Brañas,María Dolores Folgueira,José María Aguado,Alicia de Pablo-Gafas +9 more
TL;DR: Data concerning the use of leflunomide—a drug approved for rheumatoid arthritis with in vitro anticytomegalovirus activity—in lung transplant (LT) recipients are scarce.